LYS GM101

Drug Profile

LYS GM101

Alternative Names: LYS-GM101

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LYSOGENE
  • Developer Auburn University; LYSOGENE; University of Massachusetts Medical School
  • Class Gene therapies
  • Mechanism of Action Beta-galactosidase-expression-stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gangliosidoses
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gangliosidoses

Most Recent Events

  • 23 Jul 2018 Lysogene announces that pre-IND meeting with the US FDA is scheduled in 2018
  • 16 Apr 2018 Lysogene announces that scientific advice or protocol assistance from the EMA is scheduled in the first half of 2018
  • 30 Aug 2017 LYSOGENE plans a phase I/II trial in Gangliosidoses in January 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top